As the legendary investor Warren Buffett once said, forecasts about the future usually tell you more about the forecaster than they do about the future.
With the pharma industry putting the ‘blockbuster’ age behind it and moving into meeting needs across myriad niche disease areas, what is the impact and therefore change of requirement in terms of
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.